about
Guidelines for the use and interpretation of assays for monitoring autophagyGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolismInitial genome sequencing and analysis of multiple myelomaPerifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagyNovel Combination Treatments in Multiple MyelomaEmerging treatments in Castleman disease - a critical appraisal of siltuximabAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeIntegrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myelomaPhosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor GrowthTyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneOlder patients with myeloma derive similar benefit from autologous transplantation.Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.Salvage second hematopoietic cell transplantation in myelomaSecond primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.A practical update on the use of bortezomib in the management of multiple myeloma.Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.Practical considerations for multiple myeloma: an overview of recent data and current options.Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaPhase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPanobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentDeacetylase inhibitors: an advance in myeloma therapy?MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myelomaConflicts of interest, authorship, and disclosures in industry-related scientific publications.
P50
Q21996341-B776E73F-97F8-4912-9904-D195C1553A85Q22676705-B9CEB83F-B26A-4478-9AAD-A0CFE46C117CQ24300524-6FF3FC8D-EAFC-4B97-B788-259F01B7279CQ24629117-F8B6B4D0-6F6C-44BA-A59C-C93B950816D9Q24645466-02293AA3-B03A-4D86-82E7-0BFFD9303725Q26748888-578EFFE1-AFAE-44F6-88FC-A72A633BDF4FQ26766554-FD5426A5-A35F-480A-A1EB-E42764C87EF1Q26782868-A31114DC-3D0F-44BD-9E42-7821205DA5DBQ26829846-8AA4B7E5-83E9-437C-AC3F-C3A0220E7767Q27675143-ECD317E0-D10E-4752-B71F-D9785F53EADEQ27678039-FD9605D2-D8D9-4129-A265-4B50771CE7CFQ28553703-2638EBE7-6F59-478D-B345-CC9C143F80B5Q30370038-8E81B210-55A5-4FA3-8BE4-13D335B7C7AFQ30409713-FE773B51-463D-4286-8F14-9B14807B41B6Q30416452-0585DDB5-DB01-4604-8321-0AF466437655Q30756778-49EE8DE6-5B9C-4D3B-B22B-15D3FFC1B101Q33367821-950EBCB7-1C61-4A14-95FE-DDF5D07EEEA6Q33369837-90829344-0A1B-485E-94A2-20B134F7CE1EQ33372761-12118CD2-D0DA-4B97-A430-D7EEF8C5D841Q33374964-482D35D8-6D15-48BF-9382-E14F8482DFEAQ33379508-C65D0517-105B-4760-B258-9C5568FF2DD2Q33380816-25E18DEB-B5A9-4EA0-B0EA-2C15E5D5C778Q33389111-E79B766C-36D5-478F-AAAD-455E8370F55AQ33401018-DA2C290D-C13C-4AC1-BC58-A3A8DD2EED5EQ33402536-E9DB755F-14CB-4B42-9FB8-54931A943A3FQ33403690-6A039053-4F2C-46D6-8D53-C07277033251Q33407570-7623DE4C-4026-4D2B-99BC-126B09809C4AQ33409681-31DBBE94-2FAD-4DA1-80EB-0C1934D3679BQ33409825-7758BAFA-82EA-4F00-8A8E-DD7ABC476E97Q33410481-8983E118-E19E-400A-B134-81E6756999BCQ33412684-9D2C30E7-9DC2-4664-9E75-0E313F62FEC5Q33415893-08135ED9-EF05-4A26-9E1E-4331A3EF29C3Q33417762-CE1071F8-65F3-42E8-B472-F1C70221185AQ33419056-D6C81DC4-F2E9-4983-A488-1AC80089373FQ33424956-6855BB57-2A7C-48CC-8391-CCB046636003Q33427510-1F86F4C4-CECF-48C7-AEAB-A4841A7497F4Q33428098-DC7B38E1-5419-43D7-8E7E-AB8473694C94Q33438321-0BA3FD5B-EF79-4AD7-BFF5-61A3E3C03E76Q33557724-11A0FBCF-2EB4-401F-9324-A05AAE67DF54Q33620440-21925371-22EA-471B-8F33-BFC12DDF9564
P50
name
Sagar Lonial
@ast
Sagar Lonial
@en
Sagar Lonial
@nl
type
label
Sagar Lonial
@ast
Sagar Lonial
@en
Sagar Lonial
@nl
prefLabel
Sagar Lonial
@ast
Sagar Lonial
@en
Sagar Lonial
@nl
P214
P214
P31
P7859
lccn-nb2009003474